Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24157395 | 1.00 | BRPF1 (0.47) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24157211 | 0.82 | BRPF1 (0.46) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL30212561 | 0.82 | BRPF1 (0.46) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24156584 | 0.82 | BRPF1 (0.46) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24157241 | 0.80 | MGAT2 (0.34) | CREBBPPOLBPDE3BPDE3AMEN1 | |
| SCHEMBL30212699 | 0.80 | MGAT2 (0.34) | CREBBPPOLBPDE3BPDE3AMEN1 | |
| SCHEMBL14765170 | 0.80 | BRPF1 (0.44) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL31049730 | 0.78 | BRPF1 (0.42) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL25377725 | 0.78 | BRPF1 (0.42) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL15243711 | 0.78 | CREBBP (0.58) | BRPF1CREBBPGSK3BPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059929-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122036687-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036686-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010903-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4452256-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | Astrazeneca AB (SE) | 2024-10-30 | — | — | EP | disclosed |
| CN-118317793-A | Methods for treating brain tumors and neuroblastomas | 阿斯利康(瑞典)有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023118085-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4172152-A1 | QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS | Astrazeneca AB (SE) | 2023-05-03 | — | — | EP | disclosed |
| CN-115768760-A | Quinoxaline derivatives as anti-cancer agents | 阿斯利康(瑞典)有限公司 | 2023-03-07 | — | — | CN | disclosed |